Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation (Q21254711)

18 August 2022

Sue Bayliss

Sue

Bayliss

1 reference

18 August 2022

David J Moore

David J

Moore

1 reference

1013342584

18 August 2022

Martin J Connock

series ordinal

author given names

Martin J

author last names

Connock

1 reference

1013342584

Creative Commons Attribution 2.0 Generic

18 August 2022

language of work or name

English

0 references

publication date

2009

0 references

published in

BMC Endocrine Disorders

0 references

volume

0 references

issue

0 references

page(s)

0 references

start time

8 October 2009

1 reference

April 2022 Public Data File from Crossref

copyrighted

1 reference

April 2022 Public Data File from Crossref

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768727

Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768727

Medical progress: Acromegaly

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768727

Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768727

Systemic complications of acromegaly: epidemiology, pathogenesis, and management

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768727

Epidemiology of acromegaly

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768727

An audit of outcome of treatment in acromegaly.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768727

Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768727

Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2768727

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

30 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

Effects of a growth hormone receptor antagonist on bone markers in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

A nationwide survey of mortality in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

Quality of life in treated patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

Lipodystrophy in patients with acromegaly receiving pegvisomant

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

Treatment with Growth Hormone Receptor Antagonist in Acromegaly: Effect on Cardiac Structure and Performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

21 January 2018

1 reference

12 December 2020

High levels of 150-kDa insulin-like growth factor binding protein three ternary complex in patients with acromegaly and the effect of pegvisomant-induced serum IGF-I normalization

1 reference

12 December 2020

Cost-of-illness study in acromegalic patients in Italy

1 reference

12 December 2020

Quality of Life (QOL) in Patients with Acromegaly Is Severely Impaired: Use of a Novel Measure of QOL: Acromegaly Quality of Life Questionnaire

1 reference

12 December 2020

Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly

1 reference

12 December 2020

Pegvisomant interference in GH assays results in underestimation of GH levels

1 reference

12 December 2020

Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-9-20

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1186/1472-6823-9-20

1 reference

release_vlg77ez3tnahrftvok5izsjjpi

1013342584

0 references

Fatcat ID

0 references

1 reference

1 reference

PubMed publication ID

19814797

1 reference